Protocol Title: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Target Population: Metastatic Castration-Resistant Prostate Cancer

Summary: The purpose of this study is to determine how patients with Metastatic Castration-Resistant Prostate Cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with Rucaparib.

Key Inclusion Criteria:
- Be 18 years old at the time the informed consent form is signed
- Have a histologically or cytologically confirmed Adenocarcinoma or Poorly Differentiated Carcinoma of the Prostate
- Be surgically or medically castrated, with serum Testosterone levels of ≤ 50 ng/dL (1.73 nM)
- Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior Taxane-based chemotherapy, for Castration-Resistant disease
- Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency

Key Exclusion Criteria:
- Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer
- Prior treatment with any PARP Inhibitor, Mitoxantrone, Cyclophosphamide or any Platinum-based chemotherapy
- Symptomatic and/or untreated Central Nervous System metastases
- Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of Rucaparib

Contacts:
Principal Investigator: Marc Matrana, MD
Research Nurses (RN): Jessica Rentfrow (jessica.rentfrow@ochsner.org, ext. 32652)
Amanda Woolery (amanda.woolery@ochsner.org, ext. 20275)

For additional information: https://clinicaltrials.gov/ct2/show/NCT02952534